MedTrace Logo

Effects of Autogenic Inhibition and Reciprocal Inhibition in Amateur Football Players With Shin Splints.

NCT06501430 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-07-15

No results posted yet for this study

Summary

This randomized controlled trial aims to compare the effectiveness of Autogenic Inhibition and Reciprocal Inhibition in treating shin splints among amateur footballers aged 18-30 from SA Gardens Football Club, Lahore. Participants will be recruited through non-probability convenient sampling and randomly assigned into two groups using random number sampling. A single-blind approach will be employed, with one group receiving Autogenic Inhibition treatment and the other receiving Reciprocal Inhibition treatment over a period of four weeks, with three sessions per week. The study will measure outcomes including pain alleviation, improvement in range of motion (ROM), enhanced function, and improved sports performance. This research seeks to provide insights into the benefits of muscle energy techniques for athletes with shin splints, contributing valuable knowledge to sports medicine and rehabilitation practices.

Conditions

  • Shin Splint

Interventions

OTHER

Heating Therapy

Heating Therapy will be performed on subjects along with PNF Exercises.

OTHER

Manual Soft tissue Release

Manual Soft tissue Release will be performed on subjects along with PNF Exercises.

Sponsors & Collaborators

  • Riphah International University

    lead OTHER

Principal Investigators

  • Zohaib Imran · Riphah International University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-23
Primary Completion
2024-07-31
Completion
2024-07-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06501430 on ClinicalTrials.gov